FTC Pauses Illumina-Grail Order Amid 5th Circ. Appeal
The Federal Trade Commission paused an order on Monday that would prevent biotech company Illumina from fully combining with cancer test maker Grail while the businesses appeal the agency's decision to...To view the full article, register now.
Already a subscriber? Click here to view full article